Research and Markets: Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/r4nt8z/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering.

This Clostridium Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Clostridium Infections. This report provides information on the therapeutic development based on the Clostridium Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Clostridium Infections.
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information.
  • Coverage of the Clostridium Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type.
  • The report reviews key players involved in the therapeutics development for Clostridium Infections and also provide company profiling.
  • The report also gives the information of dormant and discontinued pipeline projects.
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages.
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Key Topics Covered:

  • Clostridium Infections Overview
  • Clostridium Infections Pipeline Therapeutics
  • Clostridium Infections Therapeutics under Development by Companies
  • Clostridium Infections Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Clostridium Infections Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Clostridium Infections Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Clostridium Infections Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Clostridium Infections - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Clostridium Infections - Discontinued Products
  • Clostridium Infections - Dormant Products
  • Companies Involved in Therapeutics Development for Clostridium Infections

For more information visit http://www.researchandmarkets.com/research/r4nt8z/clostridium

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals